Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6057531 | 0.83 | ACHE (0.52) | KMT2AMEN1GAAHTR6CA1 | |
| SCHEMBL9054965 | 0.79 | PTGS2 (0.48) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL14872759 | 0.78 | TDP1 (0.53) | KMT2AMEN1HTR6CA1CA2 | |
| SCHEMBL14873050 | 0.78 | CA1 (0.56) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL5202114 | 0.78 | CA1 (0.52) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL17443396 | 0.75 | KMT2A (0.54) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL10492010 | 0.75 | KMT2A (0.64) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL3690641 | 0.75 | KMT2A (0.54) | KMT2AMEN1ESR1GAAESR2 | |
| SCHEMBL5674278 | 0.75 | F2 (0.52) | KMT2AMEN1HTR6F2LMNA | |
| SCHEMBL6113188 | 0.75 | KMT2A (0.53) | KMT2AMEN1HTR6F2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324981-B1 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | PAN WENXI (US) | 2005-07-21 | — | — | US | disclosed |
| US-6900231-B2 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1324981-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6521663-B2 | For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS | 2002-05-23 | — | — | US | disclosed |
| WO-2002028825-A2 | AMINOPYRIDINYL-, AMINOGUANIDINYL- AND ALKOXYGUANIDINYL- SUBSTITUTED PHENYL ACETAMIDES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159457-A1 | Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | F12, TFPI, PLG | KMT2A 1684/4885MEN1 3793/4885ESR1 3618/4885 |
| US-20020061872-A1 | Aminopyridinyl-, aminoguanidinyl- and Alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors | TFPI, PLG, PLAT | KMT2A 1347/4885MEN1 4554/4885ESR1 4298/4885 |
| US-20030073833-A1 | Aminopyridyl-substituted phenyl acetamides as protease inhibitors | TFPI, F12, PLAT | KMT2A 1131/4885MEN1 4231/4885ESR1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.